Bleeding Disorders Market Expected to Reach $26 Billion by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “Bleeding Disorders Market," The bleeding disorders market size was valued at $13.8 billion in 2022, and is estimated to reach $26 billion by 2032, growing at a CAGR of 6.6% from 2023 to 2032. 

A bleeding disorder is a medical condition that affects the ability of the body to form blood clots and stop bleeding. There are several types of bleeding disorders, the most well-known of which is hemophilia. Hemophilia is a genetic bleeding disorder that primarily affects males and is caused by a deficiency of certain clotting factors in the blood. People with hemophilia may experience spontaneous bleeding into their joints, muscles, and organs, as well as prolonged bleeding after injury or surgery.  

Von Willebrand disease is another common bleeding disorder that affects both males and females. It is caused by a deficiency or dysfunction of Von Willebrand factor, a protein that helps blood to clot. People with Von Willebrand disease may experience nosebleeds, easy bruising, prolonged bleeding after injury or surgery, and heavy menstrual bleeding. Other rare bleeding disorders include factor deficiencies, platelet function disorders, and rare coagulation factor disorders. Treatment for bleeding disorders depends on the type and severity of the disorder and may include clotting factor replacement therapy, medications to promote clotting, and other supportive therapies. 

The growth of the bleeding disorders market share is majorly driven by rise in prevalence of bleeding disorders such as hemophilia A & B, which further increases the demand of antihemophilic drug. For instance, according to National Hemophilia Foundation (NHF) of U.S., 2023, there are 30,000-33,000 people living with hemophilia in U.S. As per the same source, 60% have severe hemophilia, 15% have moderate hemophilia And 25% have mild hemophilia.  

Moreover, increase in initiative taken by government for reducing the burden of the bleeding disorders, and increase in funding to conduct R&D activities for the development of novel therapy to treat bleeding disorders and increase in initiative taken by key players for aiding hemophilic patients drives the growth of bleeding disorders market. For instance, in May 2022, Roche announced that it has extended its commitment to the World Federation of Hemophilia (WFH) Humanitarian Aid Program until the end of 2028. The prophylactic treatment of Roche is expected to be provided to the WFH Humanitarian Aid Program to continue to treat as many as 1,000 people with hemophilia A in locations where there is little to no access to treatment. The partnership, which was originally formed by Roche and the WFH in February 2019, marked the first time that patients in developing countries had received access to a prophylactic treatment. The donated treatment has since benefited more than 940 people across 30 countries. 

In addition, surge in demand for anti-hemophilic drugs for the treatment of bleeding disorders and rise in number of clinical trials of antihemophilic drug are the key factors that drive the growth of the bleeding disorders market share in the developing countries such as India and China.  

Moreover, rise in R&D investments; significant increase in capital income in developed countries; and adoption of developmental strategies such as product launch, collaboration, merger, acquisition, and agreement by key players to stay competitive in the market foster the growth of the bleeding disorders market size. For instance, in January 2022, Takeda Pharmaceutical Company Limited announced that the U.S. Food & Drug Administration (FDA) approved VONVENDI [Von Willebrand factor (Recombinant)] for routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe Type 3 Von Willebrand disease (VWD) receiving on-demand therapy. VONVENDI is the only recombinant Von Willebrand factor (VWF) replacement therapy, and the first and only treatment to reduce the frequency of bleeding episodes for severe Type 3 VWD approved by the FDA for routine prophylactic use. VONVENDI is now indicated for routine prophylaxis in adults with severe Type 3 VWD receiving on-demand therapy, and on-demand and perioperative bleed management in adults with VWD. 

On the basis of disease type, the bleeding disorders industry is segregated into hemophilia A, hemophilia B, Von Willebrand and others, the hemophilia A segment generated maximum revenue in 2022, owing to high adoption of drugs for the treatment of hemophilia A and the availability of various medicines for hemophilia A. The same segment is expected to witness the highest CAGR during the forecast period, owing to rise in cases of hemophilia A and increase in research regarding hemophilia A.  

However, Von Willebrand segment is expected to witness considerable market growth during the forecast period. Owing to rise in cases of Von Willebrand disease, increase in number of research studies regarding Von Willebrand disease and surge in number of clinical trials of drugs for the treatment of Von Willebrand disease.

On the basis of treatment type, the bleeding disorders industry is segregated into factor replacement therapy and drug therapy, the factor replacement therapy segment dominated the market in 2022, owing to high demand for factor replacement therapy and surge in incidence of clotting factor deficient diseases. The same segment is expected to witness the highest CAGR during the forecast period, owing to an increase in the number of research, clinical trials, for the development of factor replacement therapy medicines. 

However, drug therapy segment is expected to witness considerable market growth during the forecast period. Owing to the rise in cases of perioperative prophylaxis of bleeding and rise in number of road accidents that further led to bleeding.

On the basis of distribution channel, the bleeding disorders market analysis is done on the basis of hospital pharacies, drugs stores and retail pharmacies and online pharmacies, the drugs stores and retail pharmacies segment dominated the market in 2022, owing to higher number of people take the medicined from drugs stores and retail pharmacies and surge in number of drugs stores and retail pharmacies. The hospital pharmacies segment is expected to witness the highest CAGR during the forecast period, owing to hospital pharmacy offers the precise drug according to severity of bleeding disorder in patient. Therefore, patients mostly prefer hospital pharmacy. 

However, the hospital pharmacies segment is expected to witness fastest CAGR during the forecast period.This is owing to the fact that hospital pharmacies offer the precise drug according to severity of bleeding disorder in patient. Therefore, patients mostly prefer hospital pharmacy.   

On the basis of region, North America generated maximum revenue in 2022, owing to strong presence of key players, presence of robust healthcare infrastructure, and availability of approved antihemophilic product with higher adoption of antihemophilic product. However, Asia-Pacific is expected to witness growth at the highest rate during the bleeding disorders market forecast, owing to increase in population, surge in healthcare expenditure, and rise in cases of hemophilia disease, which further increase the demand of drug for the treatment of bleeding disorders. 

Key findings of the study 

• On the basis of disease type, the hemophilia A held the largest share in the bleeding disorders market in 2022. 

• On the basis of treatment type, the factor replacement therapy dominated the market in 2022. 

• On the basis of distribution channel, the drugs stores and retail pharmacies dominated the market in 2022. 

• On the basis of region, North America garnered the bleeding disorders market trends in 2022. However, Asia-Pacific is expected to witness the highest CAGR during the forecast period.